ISC hpNSC

Drug Profile

ISC hpNSC

Alternative Names: hpNSC; Human parthenogenetic neural stem cells - International Stem Cell Corporation; ISC-hpNSC

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Duke University; International Stem Cell Corporation
  • Developer International Stem Cell Corporation; Tulane University
  • Class Antiparkinsonians; Cell therapies; Stem cell therapies
  • Mechanism of Action Dopaminergic cell replacements; Nervous system modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Parkinson's disease
  • Preclinical Brain injuries; Stroke

Most Recent Events

  • 13 Nov 2017 Efficacy and safety data from a phase I trial in Parkinson's disease released by International Stem Cell Corporation
  • 31 Oct 2017 International Stem Cell Corporation receives patent allowance for methods for generating HLA homozygous parthenogenetic human stem cell lines in Australia
  • 20 Sep 2017 International Stem Cell Corporation announces intention to submit Clinical Trial Notification to Therapeutic Goods Administration in Australia for Brain injuries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top